Literature DB >> 6415806

Inhibition of peptic aggression by sucralfate. The view from the ulcer crater.

I M Samloff.   

Abstract

Acid and pepsin have been designated the "aggressive factors" in peptic ulcer because they are essential for ulcer formation and because a reduction in their luminal concentrations is usually followed by ulcer healing. Acid enables peptic aggression by converting pepsinogen to pepsin, by providing the highly acidic pH required for pepsin activity, and by denaturing proteins, thereby increasing their susceptibility to the action of pepsin. Pepsin causes peptic aggression by hydrolyzing peptide linkages which bind together the constituent amino acids of proteins. The first step in this reaction is the formation of a complex between the active site of pepsin and the protein substrate. Sucralfate, which is the basic aluminum salt of sucrose octasulfate, inhibits this step by forming an electrostatic complex with proteins. As such, sucralfate inhibits peptic aggression without decreasing acid-pepsinogen secretion or raising intragastric pH. Because of its affinity for proteins and its insolubility and inherent viscosity in acid, sucralfate forms a physical coating over the ulcer crater. This coating further inhibits peptic aggression by producing a barrier to the diffusion of acid and pepsin. Additionally, the basic aluminum moieties of sucralfate may serve to buffer hydrogen ions as they attempt to permeate the viscous layer. The sum of these effects appears to explain the ability of sucralfate to accelerate the rate of healing of peptic ulcer.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6415806

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  4 in total

1.  Dynamic radionuclide imaging with 99mTc-sucralfate in the detection of oesophageal ulceration.

Authors:  A J Mearns; G C Hart; J A Cox
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

2.  Short term treatment of gastric ulcer: a comparison of sucralfate and cimetidine.

Authors:  B Hallerbäck; O Anker-Hansen; L Carling; H Glise; J H Solhaug; L E Svedberg; L Wählby
Journal:  Gut       Date:  1986-07       Impact factor: 23.059

Review 3.  Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

4.  Detection of inflammatory bowel disease in adults and children: evaluation of a new isotopic technique.

Authors:  D J Dawson; A N Khan; V Miller; J F Ratcliffe; D R Shreeve
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.